Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum

Susan V. Bukata, Jean Yves Blay, Piotr Rutkowski, Keith Skubitz, Robert Henshaw, Leanne Seeger, Tian Dai, Danielle Jandial, Sant Chawla

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

STUDY DESIGN: This was a subanalysis of an international, multicenter, open-label study. OBJECTIVE: The aim of this study was to assess the efficacy and safety of denosumab in a subset of patients with giant cell tumors of bone (GCTB) of the spine including the sacrum from an international, open-label, single-arm, phase 2 study (ClinicalTrials.gov: NCT00680992). SUMMARY OF BACKGROUND DATA: Standard GCTB treatment is surgical removal, either by curettage or resection, combined with intraoperative adjuvant therapy; however, some sites may not be amenable to resection (e.g., skull, spine). METHODS: Adults or skeletally mature adolescents with pathologically confirmed GCTB of the spine including the sacrum, and radiologically measurable evidence of active disease, were included. Patients received denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle. Patients had surgically unsalvageable GCTB (Cohort 1), had planned surgery expected to result in severe morbidity (Cohort 2), or were enrolled from a previous GCTB study (Cohort 3). RESULTS: Overall, 132 patients were included in the safety analysis (103 in Cohort 1, 24 in Cohort 2, and five in Cohort 3); 131 patients were included in the efficacy analysis. Kaplan-Meier estimated probabilities of disease progression or recurrence were 3% (95% confidence interval [CI], 0.0-6.2) at year 1 and 7.4% (95% CI, 2.1-12.7) at years 3 and 5 in Cohort 1, and not estimable in Cohorts 2 and 3. Of 23 patients (Cohort 2) with surgery planned at baseline, 10 (43%) had on-study surgery; of these, one patient had reported disease progression or recurrence after the on-study surgery. Clinical benefit was reported in 83% of patients overall (all cohorts). CONCLUSION: Results from the analysis suggest that denosumab is potentially effective treatment for patients with GCTB of the spine including the sacrum. The adverse event profile was consistent with the full study population.Level of Evidence: 2.

Original languageEnglish (US)
Pages (from-to)277-284
Number of pages8
JournalSpine
Volume46
Issue number5
DOIs
StatePublished - Mar 1 2021

Bibliographical note

Publisher Copyright:
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

PubMed: MeSH publication types

  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study

Fingerprint

Dive into the research topics of 'Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum'. Together they form a unique fingerprint.

Cite this